All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kellycaspersonmd on Instagram · 89s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @kellycaspersonmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00And I do prescribe testosterone to those women in early period menopause who may not need estrogen and progesterone.
  2. 0:09So just testosterone on their own because they come in telling me they are feeling demotivated, tired.
  3. 0:17Again, it's not all about sexual function. It's about their quality of life.
  4. 0:22Their body composition is changing.
  5. 0:26And then also those women who are sort of that post-menopausal who have had breast cancer treatment,
  6. 0:32who are missing out on their sex life, you know, feeling that they're gaining weight,
  7. 0:38you know, or their metabolism slowly, they feel like brain foggyness.
  8. 0:43In your view, on those patients, do you put them at a slightly higher level?
  9. 0:48Yeah, I mean, I think they do. And again, I would get them there slowly, right?
  10. 0:53Yeah, I put them on a standard dose. We can always go back up.
  11. 0:56But I think it's an important point because so many, like the myth is over-reasoned adrenals will keep making testosterone
  12. 1:03after your periods are done, right? And so they'll say, well, estrogen goes off a cliff,
  13. 1:08but then testosterone kind of does us low. And I'm like, not in my experience.
  14. 1:12There are many perimenopausal women with very low testosterone.
  15. 1:17And yeah, so I don't always believe that graph where the testosterone is falling down like over here.
  16. 1:24I'm like, no, it's falling down over here for a lot of people.
  17. 1:28Yeah, I mean...

@kellycaspersonmd's testosterone claims, fact-checked

Kelly Casperson, MD➖Urologist

Instagram creator

42.8K viewsView on Instagram

Quick answer

Dr. Casperson describes prescribing testosterone monotherapy to perimenopausal women presenting with fatigue, low motivation, and body composition changes, and discusses cautious initiation of testosterone in post-treatment breast cancer patients experiencing sexual dysfunction and metabolic symptoms. She challenges the conventional hormone trajectory model, asserting that testosterone decline begins earlier in perimenopause than standard reference graphs suggest. These are legitimate clinical observations, but they reflect her patient population rather than population-level epidemiological findings, and breast cancer survivor use remains outside current major society endorsements due to limited long-term safety data.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kellycaspersonmd's testosterone claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@kellycaspersonmd's testosterone claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kellycaspersonmd's testosterone claims, fact-checked" from Kelly Casperson, MD➖Urologist. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Dr.

The reason this review is not generic is the source wording and the canonical claim label "trt testosterone for perimenopause and even after breast cancer." In this clip, the useful excerpt is: "And I do prescribe testosterone to those women in early period menopause who may not need estrogen and progesterone." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A 2019 Lancet Diabetes and Endocrinology meta-analysis of 36 trials (Davis et al.
People who land here are usually comparing the Testosterone claim with testosteroneforwomen, perimenopausehealth, and perimenopausesupport.
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Dr.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Dr. Casperson describes prescribing testosterone monotherapy to perimenopausal women presenting with fatigue, low motivation, and body composition changes, and discusses cautious initiation of testosterone in post-treatment breast cancer patients experiencing sexual dysfunction and metabolic symptoms. She challenges the conventional hormone trajectory model, asserting that testosterone decline begins earlier in perimenopause than standard reference graphs suggest. These are legitimate clinical observations, but they reflect her patient population rather than population-level epidemiological findings, and breast cancer survivor use remains outside current major society endorsements due to limited long-term safety data.
  • Testosterone therapy for women has no FDA-approved indication in the US; all prescribing is off-label or via compounded products, meaning formulation and dosing are not standardized.
  • A 2019 Lancet Diabetes and Endocrinology meta-analysis of 36 trials (Davis et al.) found testosterone significantly improved sexual function in postmenopausal women, the strongest evidence base for this use.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Testosterone therapy for women has no FDA-approved indication in the US; all prescribing is off-label or via compounded products, meaning formulation and dosing are not standardized.
  • A 2019 Lancet Diabetes and Endocrinology meta-analysis of 36 trials (Davis et al.) found testosterone significantly improved sexual function in postmenopausal women, the strongest evidence base for this use.
  • Population-level studies show testosterone declines gradually across the menopausal transition, not sharply; individual variation is real but does not overturn the group-level data.
  • Testosterone aromatizes to estrogen in peripheral tissue, which is clinically relevant for breast cancer survivors with estrogen-sensitive tumors and should be discussed with an oncologist before starting.
  • Symptoms like fatigue, brain fog, and body composition changes overlap with thyroid dysfunction, iron deficiency, and mood disorders; testing should rule these out before attributing symptoms to low testosterone.
  • Neither NAMS nor the Endocrine Society currently recommend testosterone as routine therapy for breast cancer survivors, citing insufficient long-term safety data as of their most recent guidance updates.
  • Reference ranges for testosterone in women are poorly validated compared to men, complicating clinical interpretation of lab results even when testing is performed correctly.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @kellycaspersonmd actually say?

Dr. Casperson makes two core arguments here. First, that perimenopausal women can benefit from testosterone alone, without estrogen or progesterone, for symptoms like fatigue, brain fog, and body composition changes. Second, she pushes back on the conventional view that testosterone stays relatively stable after menopause, saying "not in my experience" and suggesting many perimenopausal women already have low testosterone before estrogen drops sharply.

She also briefly addresses breast cancer survivors, noting she starts them on a "standard dose" and titrates carefully. This is a meaningful clinical point, not a throwaway comment, because testosterone in breast cancer survivors is one of the more contested areas in women's hormonal health. She's not claiming testosterone cures anything, which is worth noting upfront.

Does the science back this up?

Partly, but it's more complicated than the video suggests. The evidence for testosterone improving libido in postmenopausal women is actually reasonably strong. Davis et al. (2019, The Lancet Diabetes and Endocrinology) conducted a systematic review and meta-analysis of 36 trials and found testosterone significantly improved sexual function in postmenopausal women. That part of the argument has real backing.

The claim that testosterone can fall early in perimenopause, before estrogen, is more debated. The Penn Ovarian Aging Study (Freeman et al., 2007, Human Reproduction) tracked hormone levels longitudinally and found testosterone decline is gradual and variable across the menopausal transition, not a cliff drop like estrogen. Some women do show low testosterone in early perimenopause. But the idea that the conventional graph is simply wrong overstates the heterogeneity in the data.

On breast cancer survivors, a 2021 pilot study by Glaser et al. (Maturitas) suggested subcutaneous testosterone may not increase breast cancer recurrence risk, but sample sizes were small and follow-up limited. This is not settled science.

What did they get wrong (or right)?

She gets credit for one thing most social media hormone content gets wrong: she explicitly says testosterone is "not all about sexual function" and frames it around quality of life and body composition. That framing is consistent with the literature. Davis et al. (2019) documented effects on wellbeing beyond libido, though those secondary outcomes had wider confidence intervals.

Where she oversimplifies: the graph she dismisses, showing testosterone declining gradually rather than sharply, is actually what most population-level data show. Her clinical observation that many of her patients have low testosterone in early perimenopause is plausible and may reflect real selection bias in who seeks care, but it is not the same as saying the population-level data is wrong. Clinical experience is not epidemiology, and conflating the two is a common error in hormone content.

Her confidence about prescribing testosterone to breast cancer survivors without more caveats is the most medically sensitive moment in this clip. The Endocrine Society and NAMS both stop short of recommending testosterone as routine therapy in breast cancer survivors due to insufficient long-term safety data.

What should you actually know?

Testosterone therapy for women is not FDA-approved in the United States for any indication, full stop. The products used are either compounded or used off-label. That is not automatically a reason to avoid it, but it means dosing, formulation, and monitoring are not standardized the way they are for male testosterone therapy.

If you are perimenopausal and experiencing fatigue, brain fog, or changes in body composition, low testosterone is one possible contributor among several. Thyroid dysfunction, iron deficiency, sleep disorders, and mood conditions can produce identical symptom profiles. Testing total and free testosterone before treatment matters, but reference ranges for women are poorly validated, which complicates interpretation.

For breast cancer survivors specifically: talk to your oncologist before starting any hormone, including testosterone. Aromatization of testosterone to estrogen is a real physiological process that is not eliminated by using testosterone instead of estrogen directly. This is not a reason to never use it, but it is a reason to have a more detailed conversation than a podcast clip allows.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kelly Casperson, MD➖Urologist · Instagram creator

42.8K views on this video

Testosterone for perimenopause and even after breast cancer treatment. This and more with @drshahzadiharper on this week’s “you are not broken” podcast. In perimenopause, sometimes testosterone is t

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about testosterone therapy for women has no fda-approved indication in the?

Testosterone therapy for women has no FDA-approved indication in the US; all prescribing is off-label or via compounded products, meaning formulation and dosing are not standardized.

What does the video say about a 2019 lancet diabetes?

A 2019 Lancet Diabetes and Endocrinology meta-analysis of 36 trials (Davis et al.) found testosterone significantly improved sexual function in postmenopausal women, the strongest evidence base for this use.

What does the video say about population-level studies show testosterone declines gradually across the menopausal transition,?

Population-level studies show testosterone declines gradually across the menopausal transition, not sharply; individual variation is real but does not overturn the group-level data.

What does the video say about testosterone aromatizes to estrogen in peripheral tissue,?

Testosterone aromatizes to estrogen in peripheral tissue, which is clinically relevant for breast cancer survivors with estrogen-sensitive tumors and should be discussed with an oncologist before starting.

What does the video say about symptoms like fatigue, brain fog,?

Symptoms like fatigue, brain fog, and body composition changes overlap with thyroid dysfunction, iron deficiency, and mood disorders; testing should rule these out before attributing symptoms to low testosterone.

What does the video say about neither nams nor the endocrine society currently recommend testosterone as?

Neither NAMS nor the Endocrine Society currently recommend testosterone as routine therapy for breast cancer survivors, citing insufficient long-term safety data as of their most recent guidance updates.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kelly Casperson, MD➖Urologist, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.